Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Amazon falls after guidance disappoints and cloud-computing growth misses estimates, Affirm jumps after fiscal second-quarter ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/104.D7q0jHs_.js ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Management guided INGREZZA sales to reach between $2.5 billion and $2.6 billion in 2025, supported by an expanded sales force and ongoing direct-to-consumer initiatives. This guidance reflects ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

BofA lowered the firm’s price target on Neurocrine (NBIX) to $179 from $184 and keeps a Buy rating on the shares after the company reported Q4 ...